HS
69 programs · 67 companies
Programs
69
Companies
67
Trials
64
MOAs
42
PRMT5iJAK1/2iWRNiIL-17iCl18.2JAK1iTYK2iAuroraAiEGFRiCFTRmod
Drugs
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-6079 | Phase 2 | MDM2 | ||
| Fixanesiran | Preclinical | RET | ||
| BMY-7975 | Phase 1 | MALT1 | ||
| Fixainavolisib | Preclinical | CDK2 | ||
| Elrarapivir | Phase 1 | GIP-R | ||
| Adagratapinarof | Preclinical | BCMA | ||
| ION-3857 | Preclinical | Nectin-4 | ||
| ILM-2412 | Phase 3 | PLK4 | ||
| Fixafutibatinib | Phase 3 | PRMT5 | ||
| Talazasiran | NDA/BLA | MET | ||
| Elrarapivir | Phase 2 | IL-13 | ||
| Terazumab | NDA/BLA | CD47 | ||
| Tezesotorasib | Phase 2 | USP1 | ||
| Bemainavolisib | NDA/BLA | PRMT5 | ||
| Motanesiran | Phase 2/3 | PLK4 | ||
| HCM-2035 | Preclinical | C5 | ||
| 209-6556 | Preclinical | GLP-1R | ||
| SWO-IIT-148 | Approved | USP1 | ||
| FRE-IIT-474 | Phase 2 | BCL-2 | ||
| STA-IIT-458 | Phase 3 | TNFα | ||
| Zanulemzoparlimab | Phase 1 | JAK2 | ||
| Surazumab | Phase 2/3 | IL-17A | ||
| QUO-3159 | Approved | PRMT5 | ||
| AVX-9264 | Phase 2/3 | CD20 | ||
| Terarelsin | Phase 3 | KRASG12C | ||
| Terafotisoran | Phase 1 | IL-13 | ||
| Motazasiran | Preclinical | BCMA | ||
| IMA-217 | NDA/BLA | HER2 | ||
| Adagraosocimab | Preclinical | DLL3 | ||
| AVE-232 | Phase 1 | B7-H3 | ||
| Sotolemzoparlimab | Phase 1 | PD-1 | ||
| ORC-1969 | Phase 1 | Tau | ||
| Rimafotisoran | Phase 2/3 | FcRn | ||
| Capiinavolisib | Phase 1/2 | IL-17A | ||
| 212-6798 | Phase 1/2 | CD19 | ||
| VES-1701 | Phase 1 | IL-13 | ||
| KAR-9558 | Approved | USP1 | ||
| Lisolemzoparlimab | Preclinical | GPRC5D | ||
| TRE-8359 | Preclinical | SMN2 | ||
| INT-5527 | Phase 2 | PD-L1 | ||
| Mavurapivir | Phase 1 | GLP-1R | ||
| ALK-4522 | Phase 1 | WRN | ||
| STA-IIT-233 | Phase 3 | CD19 | ||
| MIM-1147 | Phase 2 | TYK2 | ||
| Zorizasiran | Phase 1 | CD19 | ||
| Zorisotorasib | Approved | JAK2 | ||
| 459-1094 | Phase 3 | BTK | ||
| 128-2997 | Phase 1/2 | VEGF | ||
| AUR-9187 | Phase 2 | PD-L1 | ||
| LAU-2489 | Phase 2 | B7-H3 | ||
| Adagraderotide | Phase 1/2 | JAK2 | ||
| Ivolemzoparlimab | Approved | DLL3 | ||
| Zenosertib | Phase 2/3 | FXIa | ||
| Rimanaritide | Phase 2/3 | CDK4/6 | ||
| Niratenlimab | Phase 1 | USP1 | ||
| AUT-9774 | Phase 2/3 | BTK | ||
| Lisonaritide | Phase 1/2 | AuroraA | ||
| MOR-6182 | Phase 1/2 | TNFα | ||
| Motamavacamten | Phase 3 | BTK | ||
| Doxacapivasertib | Phase 2/3 | Aβ | ||
| RIK-IIT-251 | Phase 1/2 | USP1 | ||
| AII-IIT-879 | Preclinical | TIGIT | ||
| Adagraratamab | NDA/BLA | CFTR | ||
| Elrasacituzumab | NDA/BLA | TNFα | ||
| ATA-3814 | NDA/BLA | CD20 | ||
| Datorapivir | Phase 2/3 | IL-17A | ||
| Nirasacituzumab | Phase 2/3 | FGFR | ||
| Mavufotisoran | Approved | SMN2 | ||
| Polafotisoran | NDA/BLA | TNFα |
Trials (64)
| NCT | Drug | Phase | Status |
|---|---|---|---|
| NCT03278495 | LLY-6079 | Phase 2 | Active |
| NCT03707164 | Fixainavolisib | Preclinical | Completed |
| NCT04886249 | Fixainavolisib | Preclinical | Not yet recr... |
| NCT03526127 | Elrarapivir | Phase 1 | Active |
| NCT03704716 | Adagratapinarof | Preclinical | Completed |
| NCT08700864 | Adagratapinarof | Preclinical | Completed |
| NCT06051495 | ILM-2412 | Phase 3 | Active |
| NCT03417147 | ILM-2412 | Phase 3 | Terminated |
| NCT05130679 | ILM-2412 | Phase 3 | Active |
| NCT07204584 | Fixafutibatinib | Phase 3 | Terminated |
| NCT05516061 | Fixafutibatinib | Phase 3 | Completed |
| NCT07261753 | Fixafutibatinib | Phase 3 | Active |
| NCT06096581 | Talazasiran | NDA/BLA | Terminated |
| NCT05776913 | Elrarapivir | Phase 2 | Terminated |
| NCT06117218 | Terazumab | NDA/BLA | Recruiting |
| NCT03080257 | Terazumab | NDA/BLA | Terminated |
| NCT08320096 | Bemainavolisib | NDA/BLA | Active |
| NCT03218944 | HCM-2035 | Preclinical | Completed |
| NCT06462524 | SWO-IIT-148 | Approved | Not yet recr... |
| NCT05140292 | FRE-IIT-474 | Phase 2 | Completed |